IntrinsiQ Specialty Solutions’ New MarketTREND Tool Provides Unparalleled Market Analysis Reports to Manufacturers
August 20, 2018
Frisco, Texas - IntrinsiQ Specialty Solutions, a part of AmerisourceBergen, today announced the launch of MarketTREND, an interactive, visual tool that provides oncology manufacturers with product performance and market share analytics on a weekly basis – faster than any other comparable system on the market. By aggregating real-world treatment data from community-based private oncology practices, MarketTREND allows manufacturers direct access to the full context of product usage within the highly competitive oncology market.
“Historically, pharmaceutical companies have had to wait 30-60 days for useable utilization and adoption data. With MarketTREND, we can give this information to manufacturers on a weekly basis,” said Susan Weidner, Senior Vice President of Analytics at IntrinsiQ Specialty Solutions. “Manufacturers are eager to obtain this type of information, especially for products that are highly-targeted, entering crowded markets, or heavily used in the community oncology space. MarketTREND’s reports give manufacturers a significant competitive advantage by providing the valuable insights needed to make more informed decisions about their products more quickly.”
MarketTREND pulls treatment data from practices’ in-office dispensing and inventory management solutions. That data is compiled in an online portal, which can be segmented based on the tumor type and/or class of drug the manufacturer is seeking to analyze. Through this system, manufacturers can evaluate the drug’s uptake, market share (e.g., total treatment share vs. new patient starts), how it is performing relative to other drugs in the same category, and how it is affecting the use of those comparable drugs.
MarketTREND data can be leveraged to identify a need to shift marketing messages, reevaluate how sales teams are positioning a product for a particular line of therapy, provide additional education or address issues around dosing and side effects. With this insight, manufacturers can conduct outreach and gain valuable feedback on the drug as it is being used, putting them in the best position to drive utilization over time.
AmerisourceBergen aims to improve patient outcomes and product performance through proven solutions for commercialization and channel management. As part of AmerisourceBergen, IntrinsiQ Specialty Solutions offers analytics tools that give manufacturers and physician practices actionable business intelligence to enhance the quality of patient care and capitalize on market opportunities. For more information about IntrinsiQ Specialty Solutions, please visit www.intrinsiqanalytics.com.
AmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the pharmaceutical supply chain. Global manufacturers depend on us for services that drive commercial success for their products. Through our daily work—and powered by our 21,000 associates—we are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #12 on the Fortune 500, with more than $150 billion in annual revenue. The company is headquartered in Valley Forge, Pa. and has a presence in 50+ countries. Learn more at amerisourcebergen.com.